Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

MediLink Therapeutics (Suzhou) Co., Ltd.

MediLink Therapeutics founded in 2020, is a clinical stage biotech company focused on developing globally competitive conjugated drugs. MediLink has built a differentiated proprietary Tumor Microenviroment Activable LINker-payload (TMALIN®) ADC technology platform. It can generate homogeneous ADC, and further improve the therapeutic window in treatment of solid tumors. We focus clinical drug development on unmet medical needs and will continuously expand into new disease areas to serve the global patients. Our headquarter is located in Suzhou and has established R&D subsidiaries in Shanghai and Boston. *

 

Period Start 2020-01-01 established
  Group MediLink Therapeutics (Group)
Products Industry antibody-drug conjugate (ADC)
  Industry 2 TMALIN® ADC platform technology (Tumor Microenvironment Activable LINker-payload )
     
  City n. a. Suzhou
    Address record changed: 2023-10-15
     
Basic data Employees n. a.
     
    * Document for »About Section«: MediLink Therapeutics (Suzhou) Co., Ltd.. (10/12/23). "Press Release: MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate". Suzhou.
     
   
Record changed: 2024-01-03

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for MediLink Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top